AmerisourceBergen completes acquisition of Premier Source

NewsGuard 100/100 Score

AmerisourceBergen Corporation (NYSE: ABC) today announced that it has completed the acquisition of Premier Source, a privately held company that provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic, and biotechnology manufacturers, as well as other health services companies. The financial terms of the transaction were not disclosed.

“We are very excited about Premier Source joining AmerisourceBergen”

"We are very excited about Premier Source joining AmerisourceBergen," said Peyton Howell, President of AmerisourceBergen Consulting Services (ABCS) and Senior Vice President, Business Development of AmerisourceBergen. "Premier Source has been focused on the diagnostics market, and their business complements the work we do in both our consulting businesses under Lash Group and Xcenda."

"We are extremely pleased that our company will continue to thrive as part of AmerisourceBergen," added Sinead Foley, President of Premier Source. "The integration will help strengthen our focus on emerging diagnostic, biotech and device manufacturers; and in turn, differentiate our group."

"With our broad range of market access programs," Howell continued, "The acquisition of Premier Source provides ABCS with strategically expanded capabilities to help our business partners positively impact patients' lives."

Premier Source, headquartered in San Mateo, CA, with an office in Portland, OR, will be a business unit within ABCS, and Foley will continue with the title of President of Premier Source, reporting into Lash Group's President Tracy Foster. Founded in 2004, Premier Source offers expertise in the areas of managed care and reimbursement, particularly for life sciences companies developing novel therapies and molecular diagnostics, helping those clients eliminate barriers to coverage for their products.

Source:

 AmerisourceBergen

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-MARRVEL: A leap forward in diagnosing genetic diseases with over 98% precision